StockNews.com assumed coverage on shares of Evoke Pharma (NASDAQ:EVOK – Free Report) in a research report report published on Monday. The brokerage issued a sell rating on the specialty pharmaceutical company’s stock.
Evoke Pharma Price Performance
NASDAQ:EVOK opened at $5.72 on Monday. The stock has a 50-day simple moving average of $4.94 and a two-hundred day simple moving average of $5.51. Evoke Pharma has a 52-week low of $3.54 and a 52-week high of $17.88.
Evoke Pharma (NASDAQ:EVOK – Get Free Report) last released its earnings results on Tuesday, August 13th. The specialty pharmaceutical company reported ($0.93) EPS for the quarter, missing analysts’ consensus estimates of ($0.72) by ($0.21). The firm had revenue of $2.55 million for the quarter. Evoke Pharma had a negative return on equity of 964.25% and a negative net margin of 86.74%.
Evoke Pharma Company Profile
Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults.
Featured Articles
- Five stocks we like better than Evoke Pharma
- What is the S&P 500 and How It is Distinct from Other Indexes
- Medicare Advantage Costs Surge: How These 2 Insurers Are Thriving
- Following Congress Stock Trades
- Mobileye’s Recovery Steadily Gains Traction with Novel AI
- Investing In Automotive Stocks
- Options Traders Bet Big on These 3 Tech Stocks
Receive News & Ratings for Evoke Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evoke Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
